1% tenofovir gel

Microbicides Toolkit
Updated: October 24, 2019
Tenofovir 1% Vaginal Gel for Prevention of HIV-1 Infection in Women in South Africa (FACTS-001): a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial

The primary results of FACTS 001, a randomized, placebo-controlled trial conducted in South Africa to evaluate the safety and efficacy of 1% tenofovir vaginal gel, are presented in an article in The Lancet Infectious Diseases.

This website is made possible by the support of the American People through the United States Agency for International Development (USAID) under the Knowledge SUCCESS (Strengthening Use, Capacity, Collaboration, Exchange, Synthesis, and Sharing) Project. Knowledge SUCCESS is supported by USAID’s Bureau for Global Health, Office of Population and Reproductive Health and led by the Johns Hopkins Center for Communication Programs (CCP) in partnership with Amref Health Africa, The Busara Center for Behavioral Economics (Busara), and FHI 360. The contents of this website are the sole responsibility of CCP. The information provided on this website does not necessarily reflect the views of USAID, the United States Government, or the Johns Hopkins University. Read our full Security, Privacy, and Copyright Policies.